Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases

Kathy Foucar, Robert M. Langdon, James Olen Armitage, Daniel B. Olson, Thomas J. Carroll

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

A total of 109 patients with myelodysplastic syndromes (MDS) was analyzed to determine the clinical and pathologic features of the five recently defined French‐American‐British Cooperative Group (FAB) subtypes, and to assess the utility of this classification system in predicting survival, evolution to acute nonlymphocytic leukemia (ANLL), and cause of death. All patients with MDS presented with anemia; additional cytopenias were present in patients with refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia (CMML) and refractory anemia with excess blasts in transformation to ANLL (RAEB/Tr). Thirty‐two patients received some form of antileukemic therapy for MDS. ANLL developed in 16 of the 77 remaining untreated patients, including 18% (2/11), 0% (0/21), 22% (5/23), 33% (2/6), and 44% (7/16) of patients with refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), RAEB, CMML, and RAEB/Tr, respectively (P = 0.02). The FAB subtype was highly predictive of survival with median survivals ranging from 71 months for RARS to 5 months for RAEB/Tr (P = <0.0001). Patients with RAEB, CMML, and RAEB/Tr frequently died of direct consequences of MDS, while patients with RA and especially RARS generally survived or died from unrelated disorders (P = < 0.0001). MDS encompass a spectrum of disorders. RA and RARS, are relatively indolent and often do not lead to the patient's demise. RAEB, CMML, and RAEB/Tr are aggressive disorders which are often responsible for the patient's death whether or not actual progression to overt leukemia occurs. FAB subtype predicts survival, evolution to ANLL, and cause of death, although the five morphologic subtypes appear to separate into only two disease groups, especially with regard to survival and cause of death.

Original languageEnglish (US)
Pages (from-to)553-561
Number of pages9
JournalCancer
Volume56
Issue number3
DOIs
StatePublished - Jan 1 1985

Fingerprint

Refractory Anemia with Excess of Blasts
Myelodysplastic Syndromes
Refractory Anemia
Leukemia, Myelomonocytic, Chronic
Acute Myeloid Leukemia
Survival
Cause of Death
Lymphocyte Activation
Anemia
Leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. / Foucar, Kathy; Langdon, Robert M.; Armitage, James Olen; Olson, Daniel B.; Carroll, Thomas J.

In: Cancer, Vol. 56, No. 3, 01.01.1985, p. 553-561.

Research output: Contribution to journalArticle

Foucar, Kathy ; Langdon, Robert M. ; Armitage, James Olen ; Olson, Daniel B. ; Carroll, Thomas J. / Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. In: Cancer. 1985 ; Vol. 56, No. 3. pp. 553-561.
@article{f0dc71db055a4070bef915512f92c332,
title = "Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases",
abstract = "A total of 109 patients with myelodysplastic syndromes (MDS) was analyzed to determine the clinical and pathologic features of the five recently defined French‐American‐British Cooperative Group (FAB) subtypes, and to assess the utility of this classification system in predicting survival, evolution to acute nonlymphocytic leukemia (ANLL), and cause of death. All patients with MDS presented with anemia; additional cytopenias were present in patients with refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia (CMML) and refractory anemia with excess blasts in transformation to ANLL (RAEB/Tr). Thirty‐two patients received some form of antileukemic therapy for MDS. ANLL developed in 16 of the 77 remaining untreated patients, including 18{\%} (2/11), 0{\%} (0/21), 22{\%} (5/23), 33{\%} (2/6), and 44{\%} (7/16) of patients with refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), RAEB, CMML, and RAEB/Tr, respectively (P = 0.02). The FAB subtype was highly predictive of survival with median survivals ranging from 71 months for RARS to 5 months for RAEB/Tr (P = <0.0001). Patients with RAEB, CMML, and RAEB/Tr frequently died of direct consequences of MDS, while patients with RA and especially RARS generally survived or died from unrelated disorders (P = < 0.0001). MDS encompass a spectrum of disorders. RA and RARS, are relatively indolent and often do not lead to the patient's demise. RAEB, CMML, and RAEB/Tr are aggressive disorders which are often responsible for the patient's death whether or not actual progression to overt leukemia occurs. FAB subtype predicts survival, evolution to ANLL, and cause of death, although the five morphologic subtypes appear to separate into only two disease groups, especially with regard to survival and cause of death.",
author = "Kathy Foucar and Langdon, {Robert M.} and Armitage, {James Olen} and Olson, {Daniel B.} and Carroll, {Thomas J.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q",
language = "English (US)",
volume = "56",
pages = "553--561",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases

AU - Foucar, Kathy

AU - Langdon, Robert M.

AU - Armitage, James Olen

AU - Olson, Daniel B.

AU - Carroll, Thomas J.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - A total of 109 patients with myelodysplastic syndromes (MDS) was analyzed to determine the clinical and pathologic features of the five recently defined French‐American‐British Cooperative Group (FAB) subtypes, and to assess the utility of this classification system in predicting survival, evolution to acute nonlymphocytic leukemia (ANLL), and cause of death. All patients with MDS presented with anemia; additional cytopenias were present in patients with refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia (CMML) and refractory anemia with excess blasts in transformation to ANLL (RAEB/Tr). Thirty‐two patients received some form of antileukemic therapy for MDS. ANLL developed in 16 of the 77 remaining untreated patients, including 18% (2/11), 0% (0/21), 22% (5/23), 33% (2/6), and 44% (7/16) of patients with refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), RAEB, CMML, and RAEB/Tr, respectively (P = 0.02). The FAB subtype was highly predictive of survival with median survivals ranging from 71 months for RARS to 5 months for RAEB/Tr (P = <0.0001). Patients with RAEB, CMML, and RAEB/Tr frequently died of direct consequences of MDS, while patients with RA and especially RARS generally survived or died from unrelated disorders (P = < 0.0001). MDS encompass a spectrum of disorders. RA and RARS, are relatively indolent and often do not lead to the patient's demise. RAEB, CMML, and RAEB/Tr are aggressive disorders which are often responsible for the patient's death whether or not actual progression to overt leukemia occurs. FAB subtype predicts survival, evolution to ANLL, and cause of death, although the five morphologic subtypes appear to separate into only two disease groups, especially with regard to survival and cause of death.

AB - A total of 109 patients with myelodysplastic syndromes (MDS) was analyzed to determine the clinical and pathologic features of the five recently defined French‐American‐British Cooperative Group (FAB) subtypes, and to assess the utility of this classification system in predicting survival, evolution to acute nonlymphocytic leukemia (ANLL), and cause of death. All patients with MDS presented with anemia; additional cytopenias were present in patients with refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia (CMML) and refractory anemia with excess blasts in transformation to ANLL (RAEB/Tr). Thirty‐two patients received some form of antileukemic therapy for MDS. ANLL developed in 16 of the 77 remaining untreated patients, including 18% (2/11), 0% (0/21), 22% (5/23), 33% (2/6), and 44% (7/16) of patients with refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), RAEB, CMML, and RAEB/Tr, respectively (P = 0.02). The FAB subtype was highly predictive of survival with median survivals ranging from 71 months for RARS to 5 months for RAEB/Tr (P = <0.0001). Patients with RAEB, CMML, and RAEB/Tr frequently died of direct consequences of MDS, while patients with RA and especially RARS generally survived or died from unrelated disorders (P = < 0.0001). MDS encompass a spectrum of disorders. RA and RARS, are relatively indolent and often do not lead to the patient's demise. RAEB, CMML, and RAEB/Tr are aggressive disorders which are often responsible for the patient's death whether or not actual progression to overt leukemia occurs. FAB subtype predicts survival, evolution to ANLL, and cause of death, although the five morphologic subtypes appear to separate into only two disease groups, especially with regard to survival and cause of death.

UR - http://www.scopus.com/inward/record.url?scp=0021857744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021857744&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q

DO - 10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q

M3 - Article

VL - 56

SP - 553

EP - 561

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -